Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Diabetes is a leading cause of end-stage kidney disease (ESKD). However, the real-world data on the incidence and progression of diabetic kidney disease (DKD) in patients with newly diagnosed type 2 diabetes mellitus (T2DM) are limited. This study aimed to investigate the risk of DKD in individuals with incident T2DM using a nationwide cohort.
This study included individuals aged ≥20 years who underwent health screening in 2012–2013, had no prior history of chronic kidney disease, and had at least three follow-up examinations. Patients newly diagnosed with T2DM in 2012–2013 were classified as cases, and age- and sex-matched control (1:3) were selected. T2DM was defined as at least two occurrences of ICD-10 codes E11–E14 within one year or these codes accompanied by a prescription for antidiabetic medication. The primary outcome was a composite kidney outcome: eGFR decline to <60 mL/min/1.73 m², new-onset proteinuria, or ESKD development. In addition, the annual rate of eGFR decline was evaluated to assess longitudinal kidney function changes.
A total of 226,265 newly diagnosed T2DM patients and 678,795 matched controls were selected. The mean age was 54.98 ± 11.10 years in men and 57.54 ± 9.39 years in women. The BMI was higher in the diabetes group than in the control group for both sexes. Except for hemorrhagic stroke, the prevalence of comorbidities was higher among patients with T2DM. During a median follow-up of 9.1 years, the primary outcome occurred in 10.7% of patients with T2DM and 8.2% of controls (adjusted hazard ratio [aHR], 1.16; 95% confidence interval [CI], 1.15–1.18). Patients with T2DM exhibited a marginally greater annual decline in eGFR compared with controls (between-group difference, -0.03 mL/min/1.73 m² per year; 95% CI, -0.04 to -0.03). A similar trend was observed in a subset of T2DM patients defined solely by antidiabetic medication use. Clustering analysis of longitudinal eGFR trajectories identified distinct subgroups, including one characterized by a rapid decline in kidney function.
In patients newly diagnosed with T2DM and preserved kidney function, the overall rate of eGFR decline was only marginally greater than that in the general population. Nevertheless, the risk of developing CKD was significantly higher, highlighting the importance of early detection and targeted interventions to prevent kidney function decline in this population.
